{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:23:23Z","timestamp":1761535403358,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":1308,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1111\/jth.14211","type":"journal-article","created":{"date-parts":[[2018,6,23]],"date-time":"2018-06-23T05:44:15Z","timestamp":1529732655000},"page":"1732-1742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The pediatric acenocoumarol dosing algorithm: the Children Anticoagulation and Pharmacogenetics Study"],"prefix":"10.1016","volume":"16","author":[{"given":"H.","family":"Maagdenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.B.","family":"Bierings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.H.","family":"van Ommen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.J.M.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.M.","family":"Appel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.Y.J.","family":"Tamminga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"le Cessie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.","family":"Swen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"van der Straaten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.H.","family":"Maitland\u2010van der Zee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/jth.14211_bb0010","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2004.12.017","article-title":"Oral anticoagulation therapy in children","volume":"118","author":"Bonduel","year":"2006","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14211_bb0015","doi-asserted-by":"crossref","first-page":"e737S","DOI":"10.1378\/chest.11-2308","article-title":". Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Monagle","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.14211_bb0020","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2141.2010.08543.x","article-title":"Guideline on the investigation, management and prevention of venous thrombosis in children","volume":"154","author":"Chalmers","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.14211_bb0025","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1161\/01.cir.0000436140.77832.7a","article-title":"Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association","volume":"128","author":"Giglia","year":"2013","journal-title":"Circulation"},{"key":"10.1111\/jth.14211_bb0030","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1046\/j.1538-7836.2003.00256.x","article-title":"Acenocoumarol therapy in pediatric patients","volume":"1","author":"Bonduel","year":"2003","journal-title":"J Thromb Haemost"},{"year":"2017","series-title":"De kunst van het doseren \u2013 Richtlijn, leidraad en informatie voor het doseren van vitamine K\u2010antagonisten","key":"10.1111\/jth.14211_bb0035"},{"key":"10.1111\/jth.14211_bb0040","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1160\/TH12-04-0242","article-title":"Phenprocoumon and acenocoumarol treatment in paediatric patients","volume":"108","author":"Spoor","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14211_bb0045","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/jth.13897","article-title":"Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort","volume":"16","author":"Maagdenberg","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14211_bb0050","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/138161210790112737","article-title":"Pharmacogenetics of oral anticoagulant therapy","volume":"16","author":"Schalekamp","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1111\/jth.14211_bb0055","unstructured":"EMBL\u2010EBI. Ensembl human genome browser. Population genetics. 1000 Genomes Project Phase 3. Available at: http:\/\/www.ensembl.org\/Homo_sapiens (accessed 5 July 2017)."},{"key":"10.1111\/jth.14211_bb0060","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/tpj.2010.28","article-title":"Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs","volume":"11","author":"Wang","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"10.1111\/jth.14211_bb0065","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1093\/hmg\/ddp309","article-title":"A genome\u2010wide association study of acenocoumarol maintenance dosage","volume":"18","author":"Teichert","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1111\/jth.14211_bb0070","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/jth.12195","article-title":"Evaluation of the effects of single\u2010nucleotide polymorphisms in CYP3A4 and CYP4F2 on stable phenprocoumon and acenocoumarol maintenance doses","volume":"11","author":"van Schie","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14211_bb0075","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00204-013-1013-9","article-title":"Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms","volume":"87","author":"Daly","year":"2013","journal-title":"Arch Toxicol"},{"key":"10.1111\/jth.14211_bb0080","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenetic data","volume":"360","author":"Klein","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14211_bb0085","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1182\/blood-2011-08-372722","article-title":"VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children","volume":"119","author":"Biss","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.14211_bb0090","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood-2011-07-365502","article-title":"Vitamin\u00a0K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement","volume":"119","author":"Moreau","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.14211_bb0095","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1182\/blood-2010-05-283861","article-title":"In pediatric patients, age has more impact on dosing of vitamin\u00a0K antagonists than VKORC1 or CYP2C9 genotypes","volume":"116","author":"Nowak\u2010G\u00f6ttl","year":"2010","journal-title":"Blood"},{"key":"10.1111\/jth.14211_bb0100","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2133\/dmpk.DMPK-10-NT-082","article-title":"Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients","volume":"26","author":"Kato","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1111\/jth.14211_bb0105","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s00246-012-0592-1","article-title":"Genetic and clinical determinants influencing warfarin dosing in children with heart disease","volume":"34","author":"Nguyen","year":"2013","journal-title":"Pediatr Cardiol"},{"key":"10.1111\/jth.14211_bb0110","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/pbc.24932","article-title":"VKORC1 and CYP2C9 genotypes are predictors of warfarin\u2010related outcomes in children","volume":"61","author":"Shaw","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1111\/jth.14211_bb0115","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40291-016-0212-5","article-title":"Effect of VKORC1, CYP2C9, CFP4F2, and GGCX gene polymorphisms on warfarin dose in Japanese pediatric patients","volume":"20","author":"Wakamiya","year":"2016","journal-title":"Mol Diagn Ther"},{"key":"10.1111\/jth.14211_bb0120","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/bjh.12817","article-title":"The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population","volume":"165","author":"Vear","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.14211_bb0125","unstructured":"World Health Organization. Weight\u2010for\u2010age. Available at: http:\/\/www.who.int\/childgrowth\/standards\/weight_for_age\/en\/ (accessed 8 August 2016)."},{"key":"10.1111\/jth.14211_bb0130","unstructured":"World Health Organization. Length\/height\u2010for\u2010age. Available at: http:\/\/www.who.int\/childgrowth\/standards\/height_for_age\/en\/ (accessed 8 August 2016)."},{"key":"10.1111\/jth.14211_bb0135","unstructured":"World Health Organization. Weight\u2010for\u2010age (5\u201310\u00a0years). Available at: http:\/\/www.who.int\/growthref\/who2007_weight_for_age\/en\/ (accessed 8 August 2016)."},{"key":"10.1111\/jth.14211_bb0140","unstructured":"World Health Organization. Height\u2010for\u2010age (5\u201319\u00a0years). Available at: http:\/\/www.who.int\/growthref\/who2007_height_for_age\/en\/ (accessed 8 August 2016)."},{"key":"10.1111\/jth.14211_bb0145","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/hrt.78.2.154","article-title":"Sequelae after modified Fontan operation: postoperative haemodynamic data and organ function","volume":"78","author":"Kaulitz","year":"1997","journal-title":"Heart"},{"key":"10.1111\/jth.14211_bb0150","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/hrt.82.1.40","article-title":"Abnormalities in liver function and coagulation profile following the Fontan procedure","volume":"82","author":"van Nieuwenhuizen","year":"1999","journal-title":"Heart"},{"key":"10.1111\/jth.14211_bb0155","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jbt.20179","article-title":"Ontogeny of human hepatic cytochromes P450","volume":"21","author":"Hines","year":"2007","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1111\/jth.14211_bb0160","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1124\/jpet.103.060137","article-title":"Developmental expression of human hepatic CYP2C9 and CYP2C19","volume":"308","author":"Koukouritaki","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/jth.14211_bb0165","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00008571-199712000-00002","article-title":"Developmental expression of CYP2C and CYP2C\u2010dependent activities in the human liver: in\u2010vivo\/in\u2010vitro correlation and inducibility","volume":"7","author":"Treluyer","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1111\/jth.14211_bb0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0378-3782(99)00050-X","article-title":"Developmental changes of vitamin\u00a0K epoxidase and reductase activities involved in the vitamin\u00a0K cycle in human liver","volume":"57","author":"Itoh","year":"2000","journal-title":"Early Hum Dev"},{"key":"10.1111\/jth.14211_bb0175","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2217\/pgs.14.149","article-title":"Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands","volume":"16","author":"Verhoef","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1111\/jth.14211_bb0180","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1093\/eurheartj\/ehr116","article-title":"Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data","volume":"32","author":"van Schie","year":"2011","journal-title":"Eur Heart J"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.14211","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622023510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622023510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.14211\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:20:58Z","timestamp":1761535258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622023510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1538783622023510"],"URL":"https:\/\/doi.org\/10.1111\/jth.14211","relation":{},"ISSN":["1538-7836"],"issn-type":[{"type":"print","value":"1538-7836"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pediatric acenocoumarol dosing algorithm: the Children Anticoagulation and Pharmacogenetics Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.14211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 The Authors. Journal of Thrombosis and Haemostasis. Published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}